President Donald Trump announced from the Oval Office that Regeneron has agreed to offer its prescription medications at most-favored-nation prices, completing a sweep of 17 major pharmaceutical companies that together represent roughly 80 percent of the branded drug market in the United States. The deal, struck with one of the most prominent biotech firms in the country, extends discounted pricing to state Medicaid programs and cuts the cost of Regeneron's cholesterol drug Praluent from $537 to $225 when purchased through the administration's TrumpRx website.

That price drop alone amounts to a 58 percent reduction on a single medication. And Regeneron was the last holdout among the 17 firms the administration had targeted, as the Washington Times reported, making the announcement a capstone rather than a waypoint.

Trump, flanked by Health and Human Services Secretary Robert F. Kennedy Jr., Centers for Medicare & Medicaid Services Administrator Dr. Mehmet Oz, Commerce Secretary Howard Lutnick, and top Regeneron executives, framed the moment in blunt terms:

"With this announcement, 17 of the world's largest pharmaceutical companies, representing 80 percent of the branded drug market, have now agreed to sell their drugs to American patients at the lowest prices anywhere in the world."

The campaign to secure these deals began on September 30, when the administration announced its first agreement with Pfizer. Since then, Trump has locked in deals with AstraZeneca, EMD Serono, Eli Lilly, Novo Nordisk, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, Sanofi, Johnson & Johnson, and AbbVie, all before Regeneron signed on.

What the Regeneron agreement includes

A White House fact sheet laid out the core terms. The deal brings state Medicaid programs access to most-favored-nation pricing on new Regeneron drugs, meaning American patients on Medicaid would pay no more than patients in other developed nations pay for the same medications.

The fact sheet also states that the agreement prevents other countries from using "price controls to freeride on American innovation by guaranteeing MFN prices on all new innovative medicines Regeneron brings to market." In other words, the deal is designed to stop foreign governments from capping prices while American consumers subsidize the research behind those drugs.

Beyond pricing, the agreement requires Regeneron to repatriate increased foreign revenue on existing products "for the benefit of American patients," the fact sheet states. That revenue, generated partly as a result of the president's trade policies, would flow back into the domestic market rather than staying overseas.

The Washington Times added a significant detail: Regeneron committed to spending nearly $27 billion to bring pharmaceutical production to the United States, receiving tariff relief in exchange. That investment figure underscores the scale of the deal, it is not merely a pricing concession but a manufacturing commitment tied to the administration's broader reshoring agenda, a theme that has driven several of Trump's most consequential policy fights.

Praluent and the TrumpRx platform

The most tangible consumer-facing element of the deal centers on Praluent, Regeneron's cholesterol medication. The administration said the drug will be available for $225 through the TrumpRx website, down from $537. AP News reported that the agreement also covers lower Medicaid prices for all of Regeneron's current and future drugs, not just Praluent.

That broader scope matters. It means the deal is not a one-drug publicity gesture. It locks in pricing terms across Regeneron's entire portfolio going forward, a structural change, not a one-time discount.

The administration has used the TrumpRx site as a visible, consumer-accessible storefront for these negotiated prices. Whether that platform can handle the volume and complexity of a full drug-pricing marketplace remains an open question, but the pricing commitments from 17 companies give it a foundation that did not exist a year ago.

The broader pharmaceutical campaign

Trump's most-favored-nation drug pricing push has moved faster and further than many observers expected. The concept itself is not new, previous administrations floated versions of it, but none secured voluntary agreements from this many companies. The administration's approach has relied on a combination of negotiation, tariff leverage, and public pressure rather than the legislative route that stalled repeatedly in Congress under prior presidents.

Department of Health and Human Services chief counselor Chris Klomp signaled that the administration is not finished. Just The News reported his statement that the administration is "negotiating with the many hundreds of biotechnology and pharmaceutical companies representing that other 14%, that are building the cures for tomorrow." The 80 percent figure covers the branded drug market's largest players; the remaining share includes smaller biotech firms and specialty manufacturers.

Trump himself predicted the cumulative effect would be historic. He told reporters in the Oval Office:

"This will result in the largest drop in prescription drug prices in the history of the United States of America. I mean, it should be front page news, but it won't be. It'll be back on page 19, but the people get it. That's why we're in the Oval Office, I guess."

That comment, half boast, half media critique, captures the administration's frustration with coverage of its domestic policy wins. Whether or not every editorial page leads with the story, the underlying math is hard to dismiss: 17 companies covering 80 percent of the branded market, with pricing parity pegged to the lowest international rates.

What remains unanswered

For all its scope, the Regeneron deal leaves questions. The administration has not fully disclosed the complete terms of the agreement beyond the White House fact sheet excerpts. Newsmax noted that the full details have not been made public, a gap that matters when evaluating enforcement mechanisms and long-term durability.

Which specific new Regeneron drugs beyond Praluent fall under the agreement? What are the precise terms of access for state Medicaid programs? How will the repatriation of foreign revenue be tracked and verified? These are not trivial details. The difference between a headline-friendly announcement and a lasting policy shift often lives in the fine print.

The $27 billion manufacturing commitment also raises practical questions about timelines, facility locations, and job creation benchmarks. Tariff relief was reportedly part of the exchange, but the specifics of that relief, which tariffs, for how long, under what conditions, have not been spelled out in the available reporting. This is an area where Trump's record of striking sweeping deals will be measured by follow-through as much as by the initial announcement.

The political stakes

Drug prices hit every household. They are not an abstraction debated in think-tank white papers. They show up on pharmacy receipts, in insurance premiums, and in the monthly budgets of retirees on fixed incomes. For decades, both parties promised relief. Neither delivered at this scale.

The Trump administration's approach has been transactional, using tariff leverage and the threat of regulatory action to bring companies to the table. Critics will call it heavy-handed. But the results speak in a language voters understand: a cholesterol drug that cost $537 now costs $225. Multiply that logic across 17 companies and the branded drug market, and the potential savings for American patients are substantial.

The administration has paired this domestic push with aggressive action on other fronts, including fast-tracking FDA drug reviews for veterans' mental health and confronting institutions that resist the president's broader agenda. The common thread is a willingness to use executive leverage where Congress has failed to act.

Trump told reporters the 17 deals should be front-page news. He is right about one thing: if any previous president had secured voluntary pricing concessions from companies covering 80 percent of the branded drug market, the coverage would be wall-to-wall. The fact that it isn't tells you more about the press than about the policy.

Whether the media covers it or not, the pharmacy receipt doesn't lie. And 17 companies in a row is not a coincidence, it's a pattern. The question now is whether an administration willing to press every available lever can turn these announcements into durable, enforceable relief that outlasts the next election cycle.

Americans have been promised lower drug prices for a generation. They've never had 17 signed deals on the table at once. That's not spin. That's leverage, and it's about time somebody used it.